Taysha Gene Therapies, Inc. (TSHA)
NasdaqGS: TSHA
· 即時價格 · USD
5.02
-0.14 (-2.71%)
收盤價： Sep 11, 2026, 3:59 PM
5.02
+0.00%
盤後: 7:58 PM
股價、關鍵數字和最新消息，都在這一頁。
Taysha Gene Therapies, Inc.（TSHA）股價、分析與資料
-2.71% (1D)
| 買價 | 3.72 |
| 市值 | 1.64B |
| 營收 (ttm) | 5.49M |
| 淨利（ttm） | -150M |
| 1.17 | |
| -0.41 | |
| n/a | |
| -10.85 | |
| P/B (ttm) | 6.80 |
| P/S (ttm) | 298.21 |
| 財報日期 | Nov 4, 2026 |
| 賣價 | 6.4 |
| 成交量 | 1,777,064 |
| 20 日平均成交量 | 3,104,590 |
| 開盤價 | 5.26 |
| 前收盤價 | 5.16 |
| 當日區間 | 4.98 - 5.26 |
| 52 週範圍 | 2.71 - 7.30 |
| 分析師 | 強<br>購買 |
| 目標價 | 12.5 (149%) |
| 股利 | n/a |
| 除息日 | n/a |
關於 TSHA
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease...
完整的公司簡介財報驚奇
Taysha Gene Therapies 已於 Aug 11, 2026 公布季度財報：
- 營收為 $0 低於預期 $0, 年增 -100.00% 下滑.
- 每股盈餘為 -0.13 低於預期 -0.02, 年增 -62.50% 下滑.
第 1 頁，共 2 頁